Researchers at Northwestern University (NU) are using a blood test called TimeSignature that requires only two blood draws to tell the precise internal time clock of humans as compared to the time in the external world.

The test measures 40 different gene expression markers in the blood and can be taken any time of day, regardless of whether the patient had a good night’s sleep or was up all night with a baby.

“Timing is everything,” said study co-author Ravi Allada, a professor of neurobiology at Northwestern’s Weinberg College of Arts and Sciences. “We know if you have disruption of your internal clock, it can predispose you to a range of diseases. Virtually every tissue and organ system are governed by circadian rhythm.

“Now we can see if a disrupted clock correlates with various diseases and, more importantly, if it can predict who is going to get sick,” added Allada.

A preclinical research has identified a link between circadian misalignment and diabetes, obesity, depression, heart disease and asthma.

The researchers are envisioning improving health and treating disease by aligning people’s circadian clocks that are out of sync with external time in the next step.

“Circadian timing is a modifiable risk factor for improving cognitive health, but if we can’t measure it, it’s difficult to know if we’ve made the right diagnosis,” said co-author Phyllis Zee, chief of sleep medicine in neurology at NU Feinberg and a NU Medicine neurologist. “Now we can measure it just like a lipid level.”

“This is really an integral part of personalized medicine,” said Zee.

The test for the first time offers researchers the opportunity to easily examine the impact of misaligned circadian clocks in a range of diseases from heart disease to diabetes and Alzheimer’s disease. When the blood test eventually becomes clinically available, it also will provide doctors with a measurement of an individual’s internal biological clock to guide medication dosing at the most effective time for his or her body.

The university has filed for a patent for the blood test.

The study was published on Sept. 10 in the journal PNAS.

Original story published in Xinhua| 2018-09-12 05:02:46|Editor: yan

Ravi Allada is a member of the Chemistry of Life Processes Institute.

Chemistry of Life Processes Institute is Northwestern’s singular hub for biomedical discovery where scientists from many disciplines converge to accelerate new breakthroughs in human health and treatments for disease. Established in 2004, CLP houses four centers of research excellence and eight shared research platforms for drug discovery and development. Cutting edge facilities and PhD-level staff support investigators across the University and beyond. CLP faculty represent more than 20 University departments and three schools: Feinberg School of Medicine, McCormick School of Engineering and Weinberg School of Arts and Sciences. CLP’s rigorous training programs prepare the next generation of scientists to think, communicate and work across disciplines to find new cures, treatments and diagnostics for disease and tackle the most complex biomedical challenges of our time.

clp.northwestern.edu